Abstract 14946: Ubiquinol Improves Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Single Center, Randomized Double-Blind Placebo-Controlled Cross-Over Study
Introduction: Despite the current evidence based therapies, the outcomes of heart failure with reduced ejection fraction (HFrEF) patients remain poor. Endothelial dysfunction is reportedly associated with worse outcomes in patients with chronic heart failure. Ubiquinol is an reduced form of Coenzyme Q10 (CoQ10) which plays an important role in energy production in mitochondria. Preclinical data suggest that CoQ10 is a potent anti-inflammatory agent and may improve endothelial function.
Hypothesis: In this randomized double-blind placebo-controlled cross-over study, we assessed the hypothesis that ubiquinol improves peripheral endothelial function in patients with HFrEF.
Methods: Fourteen stable HFrEF (EF≤40%) patients were randomly and blindly allocated to ubiquinol (400mg/day) or placebo for 3 months. After 1 month wash-out, patients were crossed over to the alternative treatment. Before and after each treatment, we assessed the peripheral endothelial function with reactive hyperemia index (RHI) and analyzed using natural logarithm of RHI (LnRHI).
Results: In the 14 patients, 12 patients (86%) were male and the average of age was 70 years. Ubiquinol 400mg/day for 3 months significantly improved peripheral endothelial function (Pre LnRHI 0.45 [interquartile range 0.33 to 0.59], post LnRHI 0.55 [0.49 to 0.70], p = 0.035), but placebo did not (Pre LnRHI 0.51 [interquartile range 0.42 to 0.61], post LnRHI 0.41 [0.32 to 0.75], p = 0.55) (Figure)
Conclusions: Ubiquinol 400mg/day for 3 months provided significant and clinically meaningful improvement in peripheral endothelial function in patients with HFrEF. Ubiquinol, reduced form of CoQ10, may be a therapeutic option to treat individuals with HFrEF. Future large scale randomized controlled trials of CoQ10 supplementation in patients with HFrEF are needed.
Author Disclosures: C. Kawashima: None. Y. Matsuzawa: None. E. Akiyama: None. R. Sato: None. M. Konishi: None. H. Suzuki: None. Y. Kimura: None. T. Ebina: None. M. Kosuge: None. K. Hibi: Research Grant; Modest; AstraZeneca, MSD, Solve, Biosensors Japan, Teijin Pharma, Terumo, Mochida. Research Grant; Significant; Goodman, Medtronic Japan, St. Jude Medical Japan. Honoraria; Modest; Daiichi-Sankyo, Boston Scientific Japan. Consultant/Advisory Board; Modest; Terumo, St. Jude Medical Japan. N. Iwahashi: None. N. Maejima: None. K. Kimura: Research Grant; Significant; Toa Eiyo Ltd, Bayer, MSD, Astellas, Sanofi, Eli Lilly Japan, Research Institute for Production Development, Pfizer, Shionogi, Kowa-souyaku, Daiichi-Sankyo, Mitsubishi Tanabe, Nihon-Boehringer-Ingelheim, Takeda, Otsuka, Ono. Honoraria; Modest; Astrazeneca, Toa Eiyo Ltd. Honoraria; Significant; MSD, Bayer, Daiichi-Sankyo .
- © 2016 by American Heart Association, Inc.